These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 29334602)
1. High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. Lee JE; Lim JH; Hong YK; Yang SH Cancer Res Treat; 2018 Oct; 50(4):1331-1342. PubMed ID: 29334602 [TBL] [Abstract][Full Text] [Related]
2. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
3. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
4. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676 [TBL] [Abstract][Full Text] [Related]
5. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379 [TBL] [Abstract][Full Text] [Related]
6. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206 [TBL] [Abstract][Full Text] [Related]
7. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells. Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342 [TBL] [Abstract][Full Text] [Related]
8. Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide. Kan W; Gao L; Chen J; Chen L; Zhang G; Hao B; He M; Chen X; Wang C Mol Neurobiol; 2024 Sep; 61(9):7066-7074. PubMed ID: 38368287 [TBL] [Abstract][Full Text] [Related]
9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754 [TBL] [Abstract][Full Text] [Related]
11. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036 [TBL] [Abstract][Full Text] [Related]
14. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. Bai Y; Chen Y; Hong X; Liu X; Su X; Li S; Dong X; Zhao G; Li Y Sci Rep; 2018 Jul; 8(1):11470. PubMed ID: 30065314 [TBL] [Abstract][Full Text] [Related]
16. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540 [TBL] [Abstract][Full Text] [Related]
18. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Liu T; Li A; Xu Y; Xin Y Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175 [TBL] [Abstract][Full Text] [Related]
19. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
20. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]